期刊文献+

培美曲塞序贯吉非替尼对A549细胞凋亡的影响 被引量:1

The effects of pemetrexed+gefitinib-gefitinib sequence on apoptosis of A549 cells
下载PDF
导出
摘要 目的 探讨培美曲塞序贯吉非替尼对A549细胞的疗效,及其对A549细胞增殖、凋亡及凋亡相关蛋白表达的影响.方法 采用MTT[3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐]比色法检测培美曲塞、吉非替尼、培美曲塞联合吉非替尼及培美曲塞序贯吉非替尼对A549细胞增殖的影响;Western blot 检测凋亡相关蛋白的表达.DAPI核染色法检测A549细胞凋亡的形态学变化.结果 培美曲塞序贯吉非替尼对A549细胞增殖的抑制作用较单药及两药联合治疗更明显,A549细胞中培美曲塞、吉非替尼作用72 h的半数抑制浓度IC50分别为0.84 μmol/L和3.35 μmol/L.Western blot检测到培美曲塞序贯吉非替尼组与培美曲塞、吉非替尼单药治疗组比较,Bcl-2、Caspase3、Caspase8及PARP蛋白表达明显降低,Bax、p-H2AX蛋白表达明显升高,差异有统计学意义(P〈0.05).DAPI核染色后可观察到培美曲塞序贯吉非替尼诱导A549细胞72 h后凋亡明显增强.结论 培美曲塞、吉非替尼均可明显抑制A549细胞增殖,诱导A549细胞凋亡,培美曲塞序贯吉非替尼作用更明显. Objective To investigate the effects of pemetrexed + gefitinib - gefitinib sequence on the proliferation and apoptosis of human non - small cell lung cancer (NSCLC) A549 cells. Methods The MTF method was used to de- tect the effect of pemetrexed ( pemetrexed group) , gefitinib ( gefitinib group), combination of pemetrexed and gefitinib (pemetrexed + gefitinib group ), and pemetrexed + gefitinib - gefitinib sequence (pemetrexed + gefitinib - gefitinib group) on proliferation of A549 cells. Western blot was performed to analyze the expression of apoptosis - related proteins and the morphological changes of apoptosis were detected by DAPI staining. Results The inhibitory effects of peme- trexed or gefitinib alone and pemetrexed combined with gefitinib on A549 cells was observed. While the inhibitory effects of pemetrexed + gefitinib - gefitinib sequence were more obvious compared with pemetrexed or gefitinib alone and peme- trexed combined with gefitinib. The ICs0 ( inhibitory concentration 50% ) values of pemetrexed and gefitinib on A549 cells for 72 h were 0.84 p.mol/L and 3.35 p, mol/L, respectively. Western blot showed that compared with pemetrexed group and gefitinib group, the expression of Bel -2, caspase 3, caspase 8 and procyclic acidic repetitive proteins (PARP) in pemetrexed + gefitinib - gefitinib group was decreased, but Bax and p - H2AX was increased (P 〈 0.05 ). DAPI staining showed that the apoptosis rate of pemetrexed + gefitinib - gefitinib group on A549 cells for 72 h was the highest. Conclu- sion Both pemetrexed and gefitinib have obvious inhibitory and apoptosis effect on A549 cells, with the most prominent effect in the pemetrexed + gefitinib - gefitinib group.
出处 《徐州医学院学报》 CAS 2013年第11期759-763,共5页 Acta Academiae Medicinae Xuzhou
关键词 培美曲塞 吉非替尼 非小细胞肺癌 增殖 凋亡 pemetrexed gelitinib non- small cell lung cancer proliferation apoptosis
  • 相关文献

参考文献11

  • 1Jemal A, Center MM, Desantis C, et al. Global patterns of cancer incidence and mortality rates and trends J ]. Cancer Epidemiol B iomarkers Prev, 2010,19 ( 8 ) : 1893 - 1907.
  • 2Jemal A, Bray F, Center MM,et al. Global cancer statistics [ J]. CA Cancer J C lin, 2011,61 (2) :69 -90.
  • 3Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: New biological insights and recent therapeutic advances [JJ. CA Canc- er J Clin, 2011,61(2) :91 - 112.
  • 4Schiller JH, Harrington D, Belani CP, Comparison of four chemo- therapy regimens for advanced non - small - cell lung cancer [ J]. N Engl J Med, 2002,346(2) :92 -98.
  • 5Vogelzang N J, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma [ J ]. J Clin On- col, 2003,21 ( 14 ) :2636 - 2644.
  • 6Hanna N, Shepherd FA, Fossella FV,et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non - small - cell lung cancer previously treated with chemotherapy [ J. J Clin Oncol, 2004,22 (9) : 1589 - 1597.
  • 7孙燕,石远凯.临床肿瘤内科手册[M].5版.北京:人民卫生出版社,2011:135-146.
  • 8Curtin NJ, Harris AL, Aherne GW. Mechanism of cell death fol- lowing thymidy'late synthase inhibition : 2' - deoxyuridine - 5' - triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole [ J]. Cancer Res, 1991,51 (9) :2346 -2352.
  • 9Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non - small - cell lung cancer [ J ]. N Engl J Med. 2005.353(2) :123 - 132.
  • 10Hooijberg JH, de Vries NA, Kaspers GJ, et al. Muhidrug resist- ance proteins and folate supplementation: therapeutic implica- tions for antifolates and other classes of drugs in cancer treatment [J]. Cancer Chemother Pharmacol, 2006,58( 1 ) :1 - 12.

共引文献20

同被引文献25

  • 1Lee SM, Khan I, Upadhyay S, et al. First - line erlotinib in patients with advanced non - small - cell lung cancer unsuitable for chemo- therapy(TOP1CAL) : A double - blind, placebo - controlled, phase 3 trial [ J ]. Lancet Oncol,2012,13 ( 11 ) : 1161 - 1170.
  • 2Ettinger DS, Akerley W, Borghaei H, et al. Non - small cell lung cancer,version 2. 2013 [ J ]. J Natl Compr Canc Netw, 2013,11 (6) :645 -653.
  • 3Maemondo M, Inoue A, Kobayashi K, et at. Ge/itinib or chemothera- py for non - small - cell lung cancer with mutated EGFR [ J ]. N Engl J Med,2010,362(25) :2380 -2388.
  • 4Mitsudomi T, Morita S, Yatabe Y, et at. Gefitinib versus cisplatin plus docetaxel in patients with non - small - cell lung cancer har- bouring mutations of the epidermal growth factor receptor ( WJTOG3405 ) : An open label, randomised phase 3 trial [ J ]. Lan- cet Onco1,201 O, I 1 ( 2 ) : 121 - 128.
  • 5Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin - paclitaxel in pulmonary adenocarcinoma[ J ]. N Engl J Meal,2009, 361(10) :947 -957.
  • 6Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as firsl - line treatment for European patients with advanced EGFR mutation - positive non - small - cell lung cancer (EURTAC) : A multicentre,open - label, randomised phase 3 trial [ J ]. Lancet Oneo1,2012,13 ( 3 ) : 239 - 246.
  • 7Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previ- ously treated non - small - cell lung cancer(INTEREST) : A ran- domised phase 111 trial [ J ]. Lancet, 2008,372 ( 9652 ) : 1809 - 1818.
  • 8Maruyama R,Nishiwaki Y,Tamura T,et al. Phase In study,V - 15 -32, of gefitinib versus docetaxel in previously treated Japanese patients with non - small - cell lung cancer [ J ]. J Clin Oncol, 2008,26(26) :4244-4252.
  • 9Lee Did,Park K, Kim JI-I, et al. Randomized phase Ⅲ trial of ge- fitinib versus doeetaxel in non - small cell lung cancer patients who have previously received platinum -based chemotherapy [ J ]. Clin Cancer Res,2010,16(4) :1307 - 1314.
  • 10Kawaguchi T, Ando M, Asami K, et al. Randomized phase Ⅲ trial of edotinib versus doeetaxel as second - or third - line therapy in patients with advanced non -small -cell lung caneer: Docetaxel and erlotinib lung cancer Trial ( DELTA ) [ J ]. J Clin Oneol, 2013,32(18) :1902 - 1908.

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部